person · Reporting owner
LINDSTROM RICHARD L MD
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HARROW, INC.HROW · Entity 4740 | Director | September 30, 2022 | October 03, 2022 |
| LENSAR, Inc.LNSR · Entity 6733 | Director | June 03, 2026 | June 05, 2026 |
| OCULAR THERAPEUTIX, INCOCUL · Entity 273 | Director | June 10, 2026 | June 12, 2026 |
| TearLab CorpTEAR · Entity 147894 | Director | March 10, 2020 | March 12, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HARROW, INC.
Report date September 30, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 26,100 |
Reported balance
After 2022-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-09-30 · Sale · Disposed 40,000 · Balance 26,100 F1: The sales reported in this Form 4 were effected pursuant to a predetermined Rule 10b5-1 trading plan adopted by the reporting person during December 2021. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.03 to $12.50, inclusive. The reporting person undertakes to provide to Harrow Health, Inc. ("Harrow"), any security holder of Harrow, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Represents shares held by the Lindstrom Family Limited Partnership No 2, a limited partnership of which the reporting person is the 100% owner and sole general partner. |
| Common StockSEC Table I · non-derivative | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2022-09-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 100,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a predetermined Rule 10b5-1 trading plan adopted by the reporting person during December 2021.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.03 to $12.50, inclusive. The reporting person undertakes to provide to Harrow Health, Inc. ("Harrow"), any security holder of Harrow, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Represents shares held by the Lindstrom Family Limited Partnership No 2, a limited partnership of which the reporting person is the 100% owner and sole general partner.
LENSAR, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 263,831 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 17,421 · Balance 263,831 F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer.
OCULAR THERAPEUTIX, INC
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 260,933 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 14,000 · Balance 260,933 F1: On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.74 · Expires 2036-06-09 | Direct | 44,000 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 44,000 · Balance 44,000 F2: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
F2: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
TearLab Corp
Report date March 10, 2020 · Filed March 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2030-03-10 | Direct | 60,000 |
Reported balance
After 2020-03-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-10 · Grant · Acquired 60,000 · Balance 60,000 F1: One hundred percent (100%) of the shares subject to the Option shall be vested and exercisable upon the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to the Option shall be vested and exercisable upon the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 17:20 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $8.74 | $0.00 |
DisclosureSEC source: 0001104659-26-073584 · tm2617745-3_4seq1.xml · derivative · entry 2 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2036-06-09 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 17:20 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-073584 · tm2617745-3_4seq1.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,933 F1 · shares: On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 17:30 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 17,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-259986 · ownership.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,831 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 18:13 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | PurchaseCommon Stock | 60,229 | $7.66 | $461,354.14 |
DisclosureSEC source: 0001104659-26-019256 · tm267134-1_4seq1.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,933 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.64 to $7.69, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · balance_after: Includes 43,559 shares transferred from the Lindstrom Family No 2 Limited Partnership to the reporting person. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 16:24 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001104659-25-059388 · tm2517945-4_4seq1.xml · derivative · entry 3 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2035-06-10 F3 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 16:24 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-059388 · tm2517945-4_4seq1.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,145 F1 · shares: On June 11, 2025, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 43,559 shares owned indirectly by the reporting person that have previously been erroneously reported as directly owned. Read SEC document |
| May 23, 2025 Filed May 28, 2025 16:30 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 7,374 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-078369 · ownership.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,410 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 23, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:50 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | PurchaseCommon Stock | 10,000 | $6.96 | $69,600.00 |
DisclosureSEC source: 0001104659-25-047435 · tm2514889-1_4seq1.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,704 Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 19:30 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $7.91 | $0.00 |
DisclosureSEC source: 0001104659-24-083104 · tm2420266-5_4seq1.xml · derivative · entry 6 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2034-07-23 F4 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 19:30 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-083104 · tm2420266-5_4seq1.xml · nonDerivative · entry 3 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,704 F1 · shares: On July 24, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 07, 2024 Filed May 9, 2024 16:30 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-057107 · ownership.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,036 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 7, 2025, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| February 27, 2024 Filed Jul 26, 2024 19:30 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,363 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001104659-24-083104 · tm2420266-5_4seq1.xml · derivative · entry 5 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,363 shares Expires 2024-04-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 27, 2024, the reporting person exercised an option to purchase 11,363 shares of the Company's common stock. The option was granted on April 14, 2014, and vested over three years, vesting monthly beginning on the one-month anniversary of the Company's initial public offering. Read SEC document |
| February 27, 2024 Filed Jul 26, 2024 19:30 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,939 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001104659-24-083104 · tm2420266-5_4seq1.xml · derivative · entry 4 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,939 shares Expires 2024-04-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On February 27, 2024, the reporting person exercised an option to purchase 18,939 shares of the Company's common stock. The option was granted on April 14, 2014, and vested over four years, with 25% of the shares underlying the option vesting on April 11, 2015, and vesting monthly thereafter. Read SEC document |
| February 27, 2024 Filed Jul 26, 2024 19:30 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | Exercise / conversionCommon Stock | 11,363 | $8.80 | $99,994.40 |
DisclosureSEC source: 0001104659-24-083104 · tm2420266-5_4seq1.xml · nonDerivative · entry 2 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2024 Filed Jul 26, 2024 19:30 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | Exercise / conversionCommon Stock | 18,939 | $8.80 | $166,663.20 |
DisclosureSEC source: 0001104659-24-083104 · tm2420266-5_4seq1.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 19:05 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0001104659-23-072402 · tm2318782-4_4seq1.xml · derivative · entry 2 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2033-06-13 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 19:05 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-072402 · tm2318782-4_4seq1.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,402 F1 · shares: On June 14, 2023, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 25, 2023 Filed May 30, 2023 16:57 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 33,175 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0000899243-23-014072 · doc4.xml · derivative · entry 2 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,175 Underlying: Common Stock · 33,175 shares Expires 2033-05-25 F2 · derivative.exercise_date: The option vests in twelve (12) substantially equal monthly installments commencing June 25, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. The option was granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| May 25, 2023 Filed May 30, 2023 16:57 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 9,288 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-014072 · doc4.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,036 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 25, 2024, subject to the Reporting Person's continued service to the Issuer through the vesting date. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 18:02 UTC | HARROW, INC. HROW · Entity 4740 | SaleCommon Stock | 40,000 | $12.62 | $504,800.00 |
DisclosureSEC source: 0001493152-22-027463 · ownership.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 26,100 F1 · shares: The sales reported in this Form 4 were effected pursuant to a predetermined Rule 10b5-1 trading plan adopted by the reporting person during December 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.03 to $12.50, inclusive. The reporting person undertakes to provide to Harrow Health, Inc. ("Harrow"), any security holder of Harrow, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares held by the Lindstrom Family Limited Partnership No 2, a limited partnership of which the reporting person is the 100% owner and sole general partner. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:07 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 26,800 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001104659-22-073148 · tm2218958-3_4seq1.xml · derivative · entry 2 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,800 Underlying: Common Stock · 26,800 shares Expires 2032-06-15 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:07 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 8,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-073148 · tm2218958-3_4seq1.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,402 F1 · shares: On June 16, 2022, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 18:04 UTC | HARROW, INC. HROW · Entity 4740 | GrantRSU · Derivative | 13,123 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-016479 · ownership.xml · derivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,123 Underlying: Common Stock · 13,123 shares Expires not disclosed F1 · security: The Restricted Stock Units were received as a compensatory award for no consideration. F2 · derivative.exercise_date: Award of Restricted Stock Units vests quarterly in equal installments over a one-year period following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · derivative.expiration_date: Award of Restricted Stock Units vests quarterly in equal installments over a one-year period following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. Read SEC document |
| May 25, 2022 Filed May 27, 2022 19:54 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 15,616 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020012 · doc4.xml · derivative · entry 2 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,616 Underlying: Common Stock · 15,616 shares Expires 2032-05-25 F2 · derivative.exercise_date: The option vests in twelve (12) substantially equal monthly installments commencing June 25, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. The option was granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| May 25, 2022 Filed May 27, 2022 19:54 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 4,285 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020012 · doc4.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,748 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 25, 2023, subject to the Reporting Person's continued service to the Issuer through the vesting date. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| May 12, 2022 Filed May 16, 2022 16:13 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,469 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001104659-22-061322 · tm2215653-2_4seq1.xml · derivative · entry 2 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,469 shares Expires 2022-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, representing a right to purchase a total of 9,469 shares, became exercisable over four years, with 25% of the shares underlying the option vesting on November 1, 2013 and 2.0833% vesting monthly thereafter. Read SEC document |
| May 12, 2022 Filed May 16, 2022 16:13 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | Exercise / conversionCommon Stock | 9,469 | $1.22 | $11,552.18 |
DisclosureSEC source: 0001104659-22-061322 · tm2215653-2_4seq1.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2021 Filed Sep 27, 2021 19:31 UTC | HARROW, INC. HROW · Entity 4740 | SaleCommon Stock | 3,900 | $10.04 | $39,156.00 |
DisclosureSEC source: 0001493152-21-023910 · ownership.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 66,100 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2021 and was terminated by the reporting person on September 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.01 to $10.08, inclusive. The reporting person undertakes to provide to Harrow Health, Inc. ("Harrow"), any security holder of Harrow, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares held by the Lindstrom Family Limited Partnership No. 2, a limited partnership of which the reporting person is the general partner. Read SEC document |
| September 16, 2021 Filed Sep 17, 2021 17:15 UTC | HARROW, INC. HROW · Entity 4740 | SaleCommon Stock | 5,840 | $9.02 | $52,676.80 |
DisclosureSEC source: 0001493152-21-023036 · ownership.xml · nonDerivative · entry 2 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 70,000 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.10, inclusive. The reporting person undertakes to provide to Harrow, any security holder of Harrow, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares held by the Lindstrom Family Limited Partnership No. 2, a limited partnership of which the reporting person is the general partner. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 17:15 UTC | HARROW, INC. HROW · Entity 4740 | SaleCommon Stock | 14,160 | $9.09 | $128,714.40 |
DisclosureSEC source: 0001493152-21-023036 · ownership.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 75,840 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.98 to $9.28, inclusive. The reporting person undertakes to provide to Harrow Health, Inc. ("Harrow"), any security holder of Harrow, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares held by the Lindstrom Family Limited Partnership No. 2, a limited partnership of which the reporting person is the general partner. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 20:58 UTC | HARROW, INC. HROW · Entity 4740 | GrantRSU · Derivative | 9,644 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-015459 · ownership.xml · derivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,644 Underlying: Common Stock · 9,644 shares Expires not disclosed F1 · security: The Restricted Stock Units were received as a compensatory award for no consideration. F2 · derivative.exercise_date: Award of Restricted Stock Units vests quarterly in equal installments over a one-year period following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · derivative.expiration_date: Award of Restricted Stock Units vests quarterly in equal installments over a one-year period following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 20:01 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $13.51 | $0.00 |
DisclosureSEC source: 0001104659-21-084298 · tm2120338-3_4seq1.xml · derivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common stock · 18,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: Vests with respect to 100% of the securities on the first anniversary of the grant date. Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:05 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | SaleCommon Stock | 10,000 | $14.30 | $143,000.00 |
DisclosureSEC source: 0001104659-21-070642 · tm2117208-1_4seq1.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.23 to $14.39, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| May 20, 2021 Filed May 21, 2021 17:28 UTC | HARROW, INC. HROW · Entity 4740 | SaleCommon Stock | 10,000 | $10.75 | $107,500.00 |
DisclosureSEC source: 0001493152-21-012566 · ownership.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 90,000 F1 · ownership.nature: Represents shares held by the Lindstrom Family Limited Partnership No 2, a limited partnership of which the reporting person is the 100% owner and sole general partner. Read SEC document |
| May 18, 2021 Filed May 20, 2021 16:15 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 20,847 | $0.00 Strike: $7.49 | $0.00 |
DisclosureSEC source: 0000899243-21-020138 · doc4.xml · derivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,847 Underlying: Common Stock · 20,847 shares Expires 2031-05-18 F1 · derivative.exercise_date: The option vests in twelve (12) substantially equal monthly installments commencing June 18, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 20:48 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 32,127 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-033394 · doc4.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,463 F1 · shares: Represents restricted stock awarded to the Reporting Person on December 7, 2020 in connection with an amendment on the same date to the restricted stock awarded to him on July 22, 2020 to amend and extend the vesting schedule applicable to such award (the "Original Award"). In order to comply with tax laws and to recognize the Reporting Person's agreement to an extension of the overall vesting schedule of the Original Award, the Reporting Person was issued the restricted stock award, which represents 20% of the total number of shares subject to the Original Award. The restricted stock award will vest on the same amended vesting schedule applicable to the Original Award, which amended vesting schedule provides for vesting in quarterly installments over the approximately three-year period following the amendment date. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 16:04 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $8.75 | $0.00 |
DisclosureSEC source: 0001104659-20-077449 · a4.xml · derivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2030-06-24 F1 · derivative.exercise_date: Vests with respect to 100% of the securities on the first anniversary of the grant date. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 18:05 UTC | HARROW, INC. HROW · Entity 4740 | GrantRSU · Derivative | 17,006 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-010788 · ownership.xml · derivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,006 Underlying: Common Stock · 17,006 shares Expires not disclosed F1 · security: The Restricted Stock Units were received as a compensatory award for no consideration. F2 · derivative.exercise_date: Award of Restricted Stock Units vests quarterly in equal installments over a one-year period following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · derivative.expiration_date: Award of Restricted Stock Units vests quarterly in equal installments over a one-year period following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 16:38 UTC | TearLab Corp TEAR · Entity 147894 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001493152-20-003827 · ownership.xml · derivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-03-10 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall be vested and exercisable upon the date of grant. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 21:05 UTC | HARROW, INC. HROW · Entity 4740 | GrantRSU · Derivative | 9,715 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-009925 · ownership.xml · derivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,715 Underlying: Common Stock · 9,715 shares Expires 2020-06-26 F1 · security: Award of Restricted Stock Units vests quarterly in equal installments over a one-year period following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · security: The Restricted Stock Units were received as a compensatory award for no consideration. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 17:18 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001104659-19-035410 · a4.xml · derivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: Vests with respect to 100% of the securities on the first anniversary of the grant date. Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 16:14 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | PurchaseCommon Stock | 56,441 | $4.33 | $244,389.53 |
DisclosureSEC source: 0001104659-19-014844 · a4.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 19:52 UTC | HARROW, INC. IMMY · Entity 4740 | GrantRSU · Derivative | 34,091 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-18-009612 · ownership.xml · derivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,091 Underlying: Common Stock · 34,091 shares Expires 2019-06-29 F1 · security: Award of Restricted Stock Units vests quarterly in equal installments over a one-year period following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · security: The Restricted Stock Units were received as a compensatory award for no consideration. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 17:23 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0001104659-18-040493 · a4.xml · derivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: Vests with respect to 100% of the securities on the first anniversary of the grant date. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 18:01 UTC | HARROW, INC. IMMY · Entity 4740 | GrantRSU · Derivative | 15,723 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-17-006715 · form4.xml · derivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,723 Underlying: Common Stock · 15,723 shares Expires 2018-06-13 F1 · security: Award of Restricted Stock Units vests quarterly in equal installments over a one year period following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · security: The Restricted Stock Units were received as a compensatory award for no consideration. Read SEC document |
| June 01, 2017 Filed Jun 1, 2017 18:28 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 13,500 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001104659-17-037007 · a4.xml · derivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2027-05-31 F1 · derivative.exercise_date: Vests with respect to 100% of the securities on the first anniversary of the grant date. Read SEC document |
| April 27, 2017 Filed May 1, 2017 16:34 UTC | HARROW, INC. IMMY · Entity 4740 | OtherPurchase Warrant · Derivative | 100,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001493152-17-004611 · form4.xml · derivative · entry 5 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2019-12-27 F2 · derivative.exercise_date: The non-exercisable period for the Purchase Warrant was waived by the Company in exchange for cash exercise, the original date the warrant became exercisable was June 27, 2017. F1 · ownership.nature: Represents a contribution to the Lindstrom Family Limited Partnership No 2, a limited partnership of which the reporting person is the 100% owner and sole general partner. Read SEC document |
| April 27, 2017 Filed May 1, 2017 16:34 UTC | HARROW, INC. IMMY · Entity 4740 | GiftPurchase Warrant · Derivative | 100,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001493152-17-004611 · form4.xml · derivative · entry 4 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2019-12-27 F1 · security: Represents a contribution to the Lindstrom Family Limited Partnership No 2, a limited partnership of which the reporting person is the 100% owner and sole general partner. F2 · derivative.exercise_date: The non-exercisable period for the Purchase Warrant was waived by the Company in exchange for cash exercise, the original date the warrant became exercisable was June 27, 2017. F1 · ownership.nature: Represents a contribution to the Lindstrom Family Limited Partnership No 2, a limited partnership of which the reporting person is the 100% owner and sole general partner. Read SEC document |
| April 27, 2017 Filed May 1, 2017 16:34 UTC | HARROW, INC. IMMY · Entity 4740 | GiftPurchase Warrant · Derivative | 100,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001493152-17-004611 · form4.xml · derivative · entry 3 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2019-12-27 F1 · security: Represents a contribution to the Lindstrom Family Limited Partnership No 2, a limited partnership of which the reporting person is the 100% owner and sole general partner. F2 · derivative.exercise_date: The non-exercisable period for the Purchase Warrant was waived by the Company in exchange for cash exercise, the original date the warrant became exercisable was June 27, 2017. Read SEC document |
| April 27, 2017 Filed May 1, 2017 16:34 UTC | HARROW, INC. IMMY · Entity 4740 | OtherCommon Stock | 100,000 | $1.79 | $179,000.00 |
DisclosureSEC source: 0001493152-17-004611 · form4.xml · nonDerivative · entry 1 LINDSTROM RICHARD L MD · CIK 0001242177 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 100,000 F1 · ownership.nature: Represents a contribution to the Lindstrom Family Limited Partnership No 2, a limited partnership of which the reporting person is the 100% owner and sole general partner. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.